Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 9.7% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 190,012 shares of the company's stock after acquiring an additional 16,792 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS owned about 0.09% of Cellebrite DI worth $4,186,000 as of its most recent filing with the SEC.
Several other large investors have also recently bought and sold shares of CLBT. True Wind Capital Management L.P. boosted its holdings in shares of Cellebrite DI by 18.2% in the 4th quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company's stock valued at $305,358,000 after buying an additional 2,130,386 shares during the last quarter. FMR LLC raised its position in Cellebrite DI by 136.3% during the third quarter. FMR LLC now owns 5,616,757 shares of the company's stock worth $94,586,000 after acquiring an additional 3,239,307 shares in the last quarter. Pembroke Management LTD lifted its stake in Cellebrite DI by 4.4% in the fourth quarter. Pembroke Management LTD now owns 1,992,432 shares of the company's stock valued at $43,893,000 after acquiring an additional 84,087 shares during the last quarter. Principal Financial Group Inc. acquired a new stake in Cellebrite DI in the third quarter valued at $23,402,000. Finally, Two Sigma Advisers LP grew its position in shares of Cellebrite DI by 9.8% in the 3rd quarter. Two Sigma Advisers LP now owns 1,341,100 shares of the company's stock valued at $22,584,000 after acquiring an additional 120,000 shares during the period. 45.88% of the stock is owned by institutional investors and hedge funds.
Cellebrite DI Stock Performance
Shares of CLBT stock traded down $0.34 on Thursday, hitting $19.61. The company's stock had a trading volume of 919,423 shares, compared to its average volume of 1,124,376. Cellebrite DI Ltd. has a fifty-two week low of $10.25 and a fifty-two week high of $26.30. The stock's 50 day moving average is $20.98 and its 200-day moving average is $19.85. The company has a market capitalization of $4.70 billion, a PE ratio of -14.11, a PEG ratio of 4.27 and a beta of 1.52.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, research analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.
Analyst Ratings Changes
A number of research firms recently commented on CLBT. Lake Street Capital lifted their price target on Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, February 14th. Needham & Company LLC reiterated a "buy" rating and set a $28.00 target price on shares of Cellebrite DI in a research note on Thursday. Finally, JPMorgan Chase & Co. increased their price target on Cellebrite DI from $24.00 to $28.00 and gave the company an "overweight" rating in a research note on Tuesday, February 11th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $23.43.
Check Out Our Latest Report on CLBT
Cellebrite DI Company Profile
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
See Also
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
